This suggests that NBR1-p62-Nrf2 is a key target for the anti-oxidative stress effect of protodioscin and its anti-pulmonary fibrosis effect and may also serve as novel but promising drug target for treating pulmonary fibrosis. This evidence concerns the gene NFE2L2 and pulmonary fibrosis.